Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 7/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17410559 | 0.89 | TDP1 (0.33) | ACHEADRB2ADRB1ADRB3TSHR | |
| SCHEMBL16480956 | 0.86 | ACHE (0.38) | ACHETSHR | |
| SCHEMBL20058601 | 0.85 | TDP1 (0.31) | — | |
| SCHEMBL15634197 | 0.85 | ACHE (0.37) | CYP4F2CYP4A11ACHETSHRGLA | |
| SCHEMBL15588876 | 0.84 | ACHE (0.35) | ACHEADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL10018282 | 0.82 | SMN1; SMN2 (0.32) | SMN1; SMN2KMT2A | |
| SCHEMBL20058663 | 0.80 | — | — | |
| SCHEMBL16480953 | 0.76 | — | — | |
| SCHEMBL15634695 | 0.74 | GAA (0.38) | CYP4F2CYP4A11ACHEADRB2ADRB1 | |
| SCHEMBL10018290 | 0.74 | TDP1 (0.33) | CYP4F2CYP4A11ACHETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848711-A | 2' -chloronucleoside analogs for HCV infection | 埃迪尼克斯医药有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-2906579-B1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2906579-B1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2852605-B1 | 3',5'-CYCLIC PHOSPHATE PRODRUGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9296778-B2 | 3′,5′-cyclic phosphate prodrugs for HCV infection | IDENIX PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| EP-2906579-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX Pharmaceuticals, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140099283-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | UNIVERSITE DE MONTPELLIER (FR) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140099283-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | CYP4F2 576/4885CYP4A11 755/4885ACHE 2923/4885 |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | CYP4F2 576/4885CYP4A11 755/4885ACHE 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.